Targeted Drug Delivery Market Snapshot

“The Targeted Drug Delivery Market to grow from USD 8970 Million in 2023 to USD 25,786 Million by 2030, at a CAGR of 15.8%.”

Targeted Drug Delivery is a new way of delivering pharmaceuticals to patients that increases the concentration of the administered drug solely in the targeted bodily component of interest, such as organs, tissues, or cells.

Smart drug delivery, also known as targeted drug Delivery, is a method of administering medication to patients by adjusting the concentration of the medication in specific parts of the body.

This method, based on nanomedicine, uses nanoparticles to target diseased tissue in specific areas, avoiding interaction with healthy tissue. The goal is to prolong, localize, target, and ensure safe therapeutic interaction with sick tissue.

The standard drug delivery technique involves absorption across a biological membrane, while the targeted release system uses dose-based drug release.

This method offers benefits like reduced dosage frequency, uniform action, reduced side effects, and less variability in drug levels. However, it's expensive, making productivity difficult, and has limited capacity to change dosages.

Targeted medication delivery systems have been developed to enhance regenerative procedures by delivering therapeutic agents to sick body parts over time.

This method maintains proper drug levels, preventing harm to healthy tissue. The system is highly interconnected and requires collaboration from multiple disciplines, including chemists, biologists, and engineers, to optimize.

>>>Download Sample Report Now: https://marketreportservice.com/request-sample/targeted-drug-delivery-market-54722 

Key Insights

• Traditional drug delivery methods like oral consumption or intravascular injections only reach a small section of the diseased organ, like chemotherapy.
• Targeted drug delivery aims to concentrate medication in the targeted tissues while decreasing its concentration in other tissues.
• By evading host defense mechanisms and limiting non-specific distribution in the liver and spleen, a system can reach the intended site of action in larger quantities, increasing efficacy while decreasing negative effects.
• A targeted release system should consider factors such as drug qualities, side effects, administration route, targeted site, and disease when designing.
• Advances in targeted drug delivery to heart tissue are crucial for novel treatments, promoting cardiac tissue regeneration and preventing negative effects.
• Active targeted drug delivery, like antibody treatments, and passive targeted drug delivery, like the enhanced permeability and retention effect (EPR-effect), are two types of targeted drug delivery.

Segment Analysis

segmented by Disease Type

Most common Pulmonary Diseases

Asthma and COPD are prevalent chronic respiratory disorders affecting the lungs' airways. Asthma is characterized by recurrent episodes of shortness of breath and wheezing due to narrowing airways, varying in severity and frequency.

Three types of pulmonary disease

However, if a person is one of the millions of Americans who suffer from lung disease, they may experience breathing difficulties. Lung disease is the biggest cause of death in the United States. Asthma, pulmonary fibrosis, and pulmonary edoema are among the disorders included under the three major categories of lung disease.

In 2022, cardiovascular diseases dominated the market, accounting for 23% of total sales of 1,561 million. The lack of effective public health programs and growing demand for tailored drug administration are key factors driving market expansion.

The targeted drug delivery market is divided into three segments: first-order targeting, second-order targeting, and third-order targeting.

In 2022, the first-order segment dominated, accounting for 34% of total sales. Factors driving growth include the elimination of first-pass metabolism, lower dosage requirements, and improved therapeutic efficacy in micro doses. The demand for tailored drug administration also drives the segment's expansion.

Growth Drivers

• The number of cancer cases is increasing rapidly.
• The increase in research and development activities is being accelerated.

European Cancer Information System: 21% increase in new cancer cases by 2040.

• JRC experts predict a 21% increase in cancer diagnoses in EU and EFTA countries by 2040 due to population aging, highlighting the potential impact of aging on future cancer burden.
• Experts predict a 32% increase in cancer deaths by 2040 due to population ageing, compared to 2020.
• The European Cancer Information System published the forecasts, assuming constant cancer incidence and death levels.
• The elderly is disproportionately affected by cancer, accounting for 60% of new diagnoses and 73% of deaths in 2020.
• The general population is expected to grow at a slower rate by 2040, with cancer cases and deaths affecting the elderly more than the general population.

Restraints

The market growth is expected to be hindered by high development costs, technological issues, and clinical translational failures over the projected period.

Competitive Landscape of the Targeted Drug Delivery Market Analysis

• AstraZeneca plc.
• Bayer AG
• Pfizer
• Novartis AG
• Amgen Inc.
• Johnson and Johnson Services Inc.
• Baxter International
• Boston Scientific Corporation
• Becton
• Dickinson & Company

New Developments in Targeted Drug Delivery Market

October 10, 2023 – Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.

Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring cell therapies to patients on a global scale. The USD 250 million investment will support the production of material required for clinical trials and potential commercial launch of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson’s Disease.

BlueRock Therapeutics LP is a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG. The new facility will also support the future production of additional cell therapies as Bayer’s cell therapy portfolio advances.

Oct 26, 2023- Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers.

Novartis announced that the US Food and Drug Administration has classified the Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) drug shortage status as resolved. This determination is the result of efforts to significantly scale up production of Pluvicto that have more than doubled weekly production capacity since May.

Novartis is committed to providing a consistent, reliable supply of Pluvicto and making this important medicine readily available to patients.

June 28, 2023 – Bayer’s new pharmaceutical R&D strategy to accelerate breakthrough innovations

R&D strategy poised to translate higher quality and productivity in Bayer’s innovation model into long-term growth in four key focus areas with high unmet patient needs / Shifting to breakthrough innovations based on new scientific approaches, platforms and artificial intelligence to leverage precision medicine in Oncology, Cardiovascular Diseases, Neurology & Rare Diseases and Immunology / Today’s R&D event includes comprehensive deep dives into Bayer’s pipeline and its platform companies AskBio, BlueRock and Vividion, underpinning the company’s sustained commitment towards strategic growth investments.

Regional Analysis of Global Targeted Drug Delivery Industry

The Asia-Pacific market is predicted to grow at the fastest CAGR between 2023 and 2030 due to increasing demand for catheters, cannulas, drug delivery systems, and specialized applications. The industry is driven by increased healthcare accessibility and a growing middle-class population in China and India.

The region's advancements in medical gadgets and increased interest in home care for elderly individuals are contributing to this growth.

North America is projected to be the largest global market for targeted drug delivery in 2022, accounting for 38.2% of the market share and $2,442.7 million in revenue.

This growth is attributed to increased R&D activities by small and medium-sized businesses, as well as the high costs associated with advanced drug delivery systems in the US. Additionally, the increasing number of cancer patients contributes to the sector's growth.

Segments Covered in the Targeted Drug Delivery Market Report

Targeted Drug Delivery Market Segment by Disease Type

• Pulmonary Diseases
• Endocrine Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Oncological Disorders

Targeted Drug Delivery Market Segment By Application

• First Order Targeting [Organ Compartmentalization]
• Second Order Targeting [Cellular Targeting]
• Third Order Targeting [Intracellular Targeting]

Targeted Drug Delivery Market Segment by End-Use Industry

• Hospital
• Clinics
• Others

Targeted Drug Delivery Market by Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Rest of the World
• Middle East
• Africa
• Latin America

Frequently Asked Questions

What is targeted drug delivery systems?

Targeted drug delivery systems are designed to enhance regenerative techniques by delivering a specific amount of a therapeutic agent to a specific diseased area within the body for extended periods.

What is the expected growth rate of the Targeted Drug Delivery market over the next 7 years?

The Targeted Drug Delivery Market to grow from USD 8970 Million in 2023 to USD 25,786 Million by 2030, at a CAGR of 15.8%.

Who are the major players in the Targeted Drug Delivery market and what is their market share?

AstraZeneca plc., Bayer AG, Pfizer, Novartis AG, Amgen Inc., Johnson and Johnson Services Inc., Baxter International, Boston Scientific Corporation, Becton, Dickinson & Company, are prominent players operating and dominating in the market.

What are the advantages and disadvantages of targeted drug delivery??

The drug offers convenience, accurate dose, higher compliance, and economic benefits, but has disadvantages like unconscious patients, low solubility, gastrointestinal flora degradation, first pass metabolism, food interactions, and poor bioavailability.

Which geographical areas dominate the worldwide market for Targeted Drug Delivery?

North America region are emerging as the top regional markets for Targeted Drug Delivery solutions.